


L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS
 RN 19965-15-2 REGISTRY
 CN Platinum, bis(O-ethyl carbonodithioato-.kappa.S,.kappa.S')-, (SP-4-1)-
 (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Carbonodithioic acid, O-ethyl ester, platinum complex
 CN Platinum, bis(hydrogen dithiocarbonato)-, O,O-diethyl ester (8CI)
 CN Platinum, bis(O-ethyl carbonodithioato-S,S')-, (SP-4-1)-
 OTHER NAMES:
 CN Bis(ethyl xanthato)platinum
 CN Bis(O-ethyl dithiocarbonato)platinum
 CN Thioplatin
 DR 3444-55-1
 MF C6 H10 O2 Pt S4
 CI CCS
 LC STN Files: BIOSIS, CA, CAOLD, CAPLUS, DRUGUPDATES, GMELIN*, IFICDB,
 IFIPAT, IFIUDB, SYNTHLINE, TOXCENTER, USPATFULL
 (*File contains numerically searchable property data)



22 REFERENCES IN FILE CA (1962 TO DATE)
 22 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=>

L3 ANSWER 35 OF 35 PHARMAML COPYRIGHT 2003 MARKETLETTER

TI Antisoma in-licenses anticancer agent

AN 1654124 PHARMAML

TI Antisoma in-licenses anticancer agent

SO Marketletter October 31, 2000

DT Newsletter

WC 81

TX Antisoma in the UK has licensed-in an anticancer agent, called **thioplantin**, which has been developed by the German Cancer Research Center. **Thioplantin** has been described as a tumor-targeting version of a platin; it is only switched on by the acidic conditions found in tumor tissue and therefore is associated with greatly reduced toxicity. Antisoma feels that, although **thioplantin's** efficacy is similar to cisplatin, the reduced side effects may enable the drug to be administered in higher doses than. . .

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

188.76

191.45

STN INTERNATIONAL LOGOFF AT 10:07:52 ON 25 MAR 2003

L3 ANSWER 34 OF 35 PHARMAML COPYRIGHT 2003 MARKETLETTER

TI Antisoma cuts losses as revenues improve

AN 1655477 PHARMAML

TI Antisoma cuts losses as revenues improve

SO Marketletter February 9, 2001

DT Newsletter

WC 188

TX Moreover, Antisoma notes that: a new preclinical anti-angiogenesis development program commenced using humanized MAb BC-1; and **Thioplantin**, a tumor-targeting version of a platinum-based drug that forms the gold-standard treatment for solid tumors (including lung, ovarian and testicular. . .

L3 ANSWER 27 OF 35 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.

TI [Specific attack of **thioplantin** on tumor cells].

THIOPLATIN GREIFT TUMORZELLEN SPEZIFISCHER AN.

AN 2000421762 EMBASE

TI [Specific attack of **thioplantin** on tumor cells].

THIOPLATIN GREIFT TUMORZELLEN SPEZIFISCHER AN.

SO Pharmazeutische Zeitung, (16 Nov 2000) 145/46 (34).

ISSN: 0031-7136 CODEN: PZSED5

CY Germany

DT Journal; Note

FS 016 Cancer

037 Drug Literature Index

LA German

TI [Specific attack of **thioplantin** on tumor cells].

THIOPLATIN GREIFT TUMORZELLEN SPEZIFISCHER AN.

CT Medical Descriptors:

*tumor cell: DT, drug therapy

antineoplastic activity

cytostasis

cancer chemotherapy

glucose metabolism

human

note

*cisplatin derivative: DT, drug therapy

***thioplantin**: DT, drug therapy

antineoplastic agent: DT, drug therapy

unclassified drug

L3 ANSWER 28 OF 35 ADISINSIGHT COPYRIGHT 2003 (ADIS)

CN **Thioplantin**

TX TEXT

Introduction:

~~Thioplantin~~ is a tumour-targeted version of a platin that is switched on only in the acidic conditions typically found in. . . doses of platinum to be used which in turn should create higher therapeutic efficacy and reduced toxicity. Antisoma has licensed **thioplantin** from the originators of the compound at the German Cancer Research Centre in Heidelberg, Germany, through an agreement negotiated between. . . independent technology transfer company created by the Cancer Research Campaign to provide services for commercialisation to cancer research institutions worldwide. **Thioplantin** is currently in preclinical development, with the agent showing good activity in controlling the growth of non-small cell lung cancer in animal models. Further work on the formulation is being conducted before **thioplantin** can enter clinical trials. This means that **thioplantin** will not start clinical studies in 2002 as originally anticipated.

The company has a cooperation and supply agreement with W.C. Heraeus GmbH & Co. KG of Germany to develop methods for producing the active ingredients for **thioplantin**.

Financial Figures

The Financial Time (ft.com) reported on March 5, 2001 that branded platinum products have annual sales. . . that it had plans to raise up to Lstg 12 million (\$US17.6 million) to fund development of compounds such as **thioplantin**, which was in-licensed in October 2000; Antisoma was also looking at extending its current product pipeline.

TX PHARMACOLOGY:

Pharmacodynamics (Cancer):

Preclinical studies: preliminary results from in vitro studies have shown

that **thioplantin** was active in 3 human ovarian cancer cell lines that had acquired resistance to cisplatin/1/.

L3 ANSWER 29 OF 35 DRUGU COPYRIGHT 2003 THOMSON DERWENT
AN 84055 DRUGU
FS Registry
DDRN DR0053595
DDN **THIOPLATIN**
CT CYTOSTATICS
SS COMPLEX; XANTHOGENATE; PLATINUM-COMPLEX
DDN **THIOPLATIN**

TI Antisoma licenses new anticancer
AN 2000:19551 PHIN
DN S00685590
DED 8 Nov 2000
TI Antisoma licenses new anticancer
SO Scrip (2000) No. 2590 p8
DT Newsletter
FS BRIEF
TX The UK biotechnology company, Antisoma, has licensed **Thioplantin**,
a new "platin" anticancer agent from the German Cancer Research Centre in
Heidelberg. The terms of the deal were not. . .

L3 ANSWER 26 OF 35 PHIN COPYRIGHT 2003 PJB

TI PHARMAPROJECTS - New Anticancer Products for week ending 03 November 2000
AN 2000:20176 PHIN
DN S00686592
DED 7 Nov 2000
TI PHARMAPROJECTS - New Anticancer Products for week ending 03 November 2000
SO Scrip-Online-plus (2000)
DT Newsletter
FS FULL
TX

Anticancer, alkylating (K1B)

Product Name	Originator
--------------	------------

Thioplantin	Antisoma
-------------	----------

Radio/chemosensitizer (K5A)

Product Name	Originator
--------------	------------

tesmilifene	York Medical
-------------	--------------

Anticancer, other (K6Z)

Product Name	Originator
--------------	------------

Apollo technology	Procter & Gamble
-------------------	------------------

L3 ANSWER 27 OF 35 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
TI [Specific attack of **thioplantin** on tumor cells].
THIOPLATIN GREIFT TUMORZELLEN SPEZIFISCHER AN.
AN 2000421762 EMBASE
TI [Specific attack of **thioplantin** on tumor cells].
THIOPLATIN GREIFT TUMORZELLEN SPEZIFISCHER AN.
SO Pharmazeutische Zeitung, (16 Nov 2000) 145/46 (34).
ISSN: 0031-7136 CODEN: PZSED5
CY Germany
DT Journal; Note

TI COMPANY NEWS - Antisoma plc (UK)
 AN 2001:733 PHIN
 DN B00690682
 DED 1 Dec 2000
 TI COMPANY NEWS - Antisoma plc (UK)
 SO Bioventure-View (2000) No. 1512 p27
 DT Newsletter
 FS BRIEF
 TX Antisoma plc London, UK (Easdaq: ASOM / LSE: ASM) Antisoma has
 in-licensed **Thioplatin**, a tumour targeting version of platin,
 from the German Cancer Research Centre. Platin is a platinum-based drug
 class that forms. . .

L3 ANSWER 25 OF 35 PHIN COPYRIGHT 2003 PJB

TI Antisoma licenses new anticancer
 AN 2000:19551 PHIN
 DN S00685590
 DED 8 Nov 2000
 TI Antisoma licenses new anticancer
 SO Scrip (2000) No. 2590 p8
 DT Newsletter
 FS BRIEF
 TX The UK biotechnology company, Antisoma, has licensed **Thioplatin**,
 a new "platin" anticancer agent from the German Cancer Research Centre in
 Heidelberg. The terms of the deal were not. . .

L3 ANSWER 26 OF 35 PHIN COPYRIGHT 2003 PJB

TI PHARMAPROJECTS - New Anticancer Products for week ending 03 November 2000
 AN 2000:20176 PHIN
 DN S00686592
 DED 7 Nov 2000
 TI PHARMAPROJECTS - New Anticancer Products for week ending 03 November 2000
 SO Scrip-Online-plus (2000)
 DT Newsletter
 FS FULL
 TX

Anticancer, alkylating (K1B)

Product Name	Originator
Thioplatin	Antisoma

Radio/chemosensitizer (K5A)

Product Name	Originator
tesmilifene	York Medical

Anticancer, other (K6Z)

Product Name	Originator
Apollo technology	Procter & Gamble

L3 ANSWER 27 OF 35 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
 TI [Specific attack of **thioplatin** on tumor cells].
THIOPLATIN GREIFT TUMORZELLEN SPEZIFISCHER AN.
 AN 2000421762 EMBASE
 TI [Specific attack of **thioplatin** on tumor cells].
THIOPLATIN GREIFT TUMORZELLEN SPEZIFISCHER AN.

SO Pharmazeutische Zeitung, (16 Nov 2000) 145/46 (34).

ISSN: 0031-7136 CODEN: PZSED5

CY Germany

DT Journal; Note

FS 016 Cancer

037 Drug Literature Index

LA German

TI [Specific attack of **thioplantin** on tumor cells].

THIOPLATIN GREIFT TUMORZELLEN SPEZIFISCHER AN.

CT Medical Descriptors:

*tumor cell: DT, drug therapy

antineoplastic activity

cytostasis

cancer chemotherapy

glucose metabolism

human

note

*cisplatin derivative: DT, drug therapy

***thioplantin: DT, drug therapy**

antineoplastic agent: DT, drug therapy

unclassified drug

L3 ANSWER 28 OF 35 ADISINSIGHT COPYRIGHT 2003 (ADIS)

CN **Thioplantin**

TX TEXT

Introduction:

Thioplantin is a tumour targeted version of a platin that is switched on only in the acidic conditions typically found in. . . doses of platinum to be used which in turn should create higher therapeutic efficacy and reduced toxicity. Antisoma has licensed **thioplantin** from the originators of the compound at the German Cancer Research Centre in Heidelberg, Germany, through an agreement negotiated between. . . independent technology transfer company created by the Cancer Research Campaign to provide services for commercialisation to cancer research

TI **Thioplatin** Platinum-Based, Targeted Anti-Cancer Therapy
In-Licensed.
AN 2000:309550 NLDB
TI **Thioplatin** Platinum-Based, Targeted Anti-Cancer Therapy
In-Licensed.
SO Cancer Weekly, (14 Nov 2000) .
PB Charles W. Henderson
DT Newsletter
LA English
WC 221
TI **Thioplatin** Platinum-Based, Targeted Anti-Cancer Therapy
In-Licensed.
TX **Thioplatin** is a tumor-targeting version of a platin, the "gold
standard," platinum-based drug class that forms the cornerstone of cancer
treatments. . .

Thioplatin, which was developed by Dr. Eberhard Amtmann at
DKFZ in Heidelberg in collaboration with a chemist at the University of.
. . Heidelberg, is only "switched on" by the acidic conditions typically
found in tumors, leaving healthy tissues essentially undamaged.
Experiments using **Thioplatin** in isolated tumor cells and in
animal models have shown that, while its efficacy is similar to that of
the widely-used platinum-based drug cisplatin, its toxicity is strongly
reduced. This indicates that it may be possible to give **Thioplatin**
in higher doses than conventional platinum-based drugs, thereby
potentially increasing the cancer-killing effect. The drug is expected to
enter clinical. . .

L3 ANSWER 24 OF 35 PHIN COPYRIGHT 2003 PJB

TI COMPANY NEWS - Antisoma plc (UK)
AN 2001:733 PHIN
DN B00690682
DED 1 Dec 2000
TI COMPANY NEWS - Antisoma plc (UK)
SO Bioventure-View (2000) No. 1512 p27.
DT Newsletter
FS BRIEF
TX Antisoma plc London, UK (Easdaq: ASOM / LSE: ASM) Antisoma has
in-licensed **Thioplatin**, a tumour targeting version of platin,
from the German Cancer Research Centre. Platin is a platinum-based drug
class that forms. . .

L3 ANSWER 25 OF 35 PHIN COPYRIGHT 2003 PJB

TI Antisoma licenses new anticancer
AN 2000:19551 PHIN
DN S00685590
DED 8 Nov 2000
TI Antisoma licenses new anticancer
SO Scrip (2000) No. 2590 p8
DT Newsletter
FS BRIEF
TX The UK biotechnology company, Antisoma, has licensed **Thioplatin**,
a new "platin" anticancer agent from the German Cancer Research Centre in
Heidelberg. The terms of the deal were not. . .

L3 ANSWER 26 OF 35 PHIN COPYRIGHT 2003 PJB

TI PHARMAPROJECTS - New Anticancer Products for week ending 03 November 2000
AN 2000:20176 PHIN
DN S00686592
DED 7 Nov 2000

TI PHARMAPROJECTS - New Anticancer Products for week ending 03 November 2000
SO Scrip-Online-plus (2000)
DT Newsletter
FS FULL

TI Antisoma in-licenses anticancer agent.
AN 2000:296476 NLDB
TI Antisoma in-licenses anticancer agent.
SO Marketletter, (6 Nov 2000) .
ISSN: 0951-3175.
PB Marketletter Publications Ltd.
DT Newsletter
LA English
WC 81
TX

Antisoma in the UK has licensed-in an anticancer agent, called **thioplantin**, which has been developed by the German Cancer Research Center. **Thioplantin** has been described as a tumor-targeting version of a platin; it is only switched on by the acidic conditions found in tumor tissue and therefore is associated with greatly reduced toxicity. Antisoma feels that, although **thioplantin**'s efficacy is similar to cisplatin, the reduced side effects may enable the drug to be administered in higher doses than. . .

TI OTHER NEWS TO NOTE.
AN 2000:292514 NLDB
TI OTHER NEWS TO NOTE.
SO BIOWORLD Today, (31 Oct 2000) Vol. 11, No. 211.
PB American Health Consultants, Inc.
DT Newsletter
LA English
WC 1326
TX Antisoma . . . anticancer agent from the German Cancer Research
Center, of Heidelberg, Germany. No financial terms were disclosed in the
deal for **thioplantin**, a tumor-targeting version of a platin, a
platinum-based solid tumor therapeutic.

L3 ANSWER 6 OF 35 IFIPAT COPYRIGHT 2003 IFI DUPLICATE 1
 TI MEDICAMENT CONTAINING PLATINUM COMPLEX COMPOUNDS AND THE USE THEREOF;
 ANTICANCER AGENTS
 AN 10061018 IFIPAT;IFIUDB;IFICDB
 TI MEDICAMENT CONTAINING PLATINUM COMPLEX COMPOUNDS AND THE USE THEREOF;
 ANTICANCER AGENTS
 INF Amtmann; Eberhard, Heidelberg, DE
 Schilling; Gerhard, Ladenburg, DE
 IN Amtmann Eberhard (DE); Schilling Gerhard (DE)
 PAF Unassigned
 PA Unassigned Or Assigned To Individual (68000)
 AG PALMER & DODGE, LLP, ONE BEACON STREET, BOSTON, MA, 02108-3190, US
 PI US 2002004526 A1 20020110
 AI US 2001-784618 20010215
 PRAI DE 1998-19838547 19980825
 FI US 2002004526 20020110
 DT Utility; Patent Application - First Publication
 FS CHEMICAL
 APPLICATION
 CLMN 11
 GI 5 Figure(s).
 FIG. 1 tumor regression and growth, respectively, after the treatment of a
 parvocellular bronchial carcinoma with a compound according to the
 invention and control, respectively,
 FIG. 2 anti-tumoral effect of a compound according to the invention on a
 human colon carcinoma in naked mice,
 FIG. 3 pH value-dependent effectiveness of cytostatic agents,
 FIG. 4 anti-tumoral effect of **thioplantin** on human
 xenotransplants,
 FIG. 5 histopathology of kidney and small intestine after treatment with
thioplantin and cisplatin.
 AB The present invention relates to a pharmaceutical preparation containing
 at least one compound of general formula (I)

D R A W I N G

wherein R1 and R2 are each independently of each other a straight-chain
 or branched alkyl residue having 1 to 30 carbon atoms, a straight-chain
 or branched alkenyl residue having 2 to 30 carbon atoms, a monocyclic or
 polycyclic alkyl residue having 3 to 30 carbon atoms, a monocyclic or
 polycyclic alkenyl residue having 4 to 30 carbon atoms, or a monocyclic
 or polycyclic aromatic residue having 6 to 30 carbon atoms, these
 residues being optionally substituted by one or several substituents.
 This invention also relates to the use of the pharmaceutical preparations
 for the immunosuppressive treatment and for the non-invasive treatment.
 GI
 invention on a human colon carcinoma in naked mice,
 FIG. 3 pH value-dependent effectiveness of cytostatic agents,
 FIG. 4 anti-tumoral effect of **thioplantin** on human
 xenotransplants,
 FIG. 5 histopathology of kidney and small intestine after treatment with
thioplantin and cisplatin.
 L3 ANSWER 7 OF 35 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.DUPLICATE
 2
 TI **Thioplantin**: A sulfur-containing platinum complex possessing
 greater activity in acidic pH, non-cross resistance with cisplatin and
 antitumor activity in vivo.
 AN 2002:367409 BIOSIS
 DN PREV200200367409
 TI **Thioplantin**: A sulfur-containing platinum complex possessing
 greater activity in acidic pH, non-cross resistance with cisplatin and
 antitumor activity in vivo.

AU Rowlinson-Busza, Gail (1); Griffiths-Johnson, David (1); Hadfield,